Norswertianolin

Research use only, not for human use.

Norswertianolin, a compound isolated from G. acuta, functions as a CSE activator and shows promise as a potential cardiovascular therapeutic.

Norswertianolin, a compound isolated from G. acuta, functions as a CSE activator and shows promise as a potential cardiovascular therapeutic.

Norswertianolin (3.125~50 μM; H9c2 cells) has the protective effects on H2O2-induced H9c2 cells. Norswertianolin significantly increases the transcription levels of HO-1 and GCLC in H9c2 cells. Norswertianolin (0~150 μM; HepG2 cells) high concentration increases the CSE protein level.

Norswertianolin (4.4 mg/kg/day; s.c.; 1 week) improves CSE/H2S production.Norswertianolin treatment attenuates the renal tubular injury in acute I/R. Norswertianolin also reduces I/R-stimulated ROS by DHE fluorescence intensity. Norswertianolin has anti-hypertension effects, inhibits vascular remodeling and reduces inflammation effects. Animal Model:Male Sprague Dawley rats (10~12 weeks ) Dosage:4.4 mg/kg/day Administration:S.c.Result:Improved CSE/H2S production.

——

Others

Other Targets

——

——

——

54954-12-0

422.34

C19H18O11

>98% (HPLC)

In Vitro:?DMSO : 25 mg/mL (59.19 mM)

——

——

(-20℃)

With Ice Pack

≥ 2 years